about
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.Building proteomic tool boxes to monitor MHC class I and class II peptides.Rejection versus escape: the tumor MHC dilemma.A Review of Immune Therapy in Cancer and a Question: Can Thermal Therapy Increase Tumor Response?Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors.HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activationMutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape.
P2860
Q37575208-C15747AD-FC9C-4A30-82BF-AE0559EC8F32Q39032610-E6E8D53A-FC67-4AC9-828F-6DB3C2AA5774Q39063943-67E1D967-FD91-45B2-8F8F-B75981BC376CQ41928232-D74BE54E-EFC9-44C0-83F9-831FBCC14C89Q41945124-D9ED8F5F-BB57-4A3A-B11A-E6823BCC0FA5Q42702294-2BE50CA6-73D8-4722-9ADD-98BA5163B002Q47157659-687031EE-A454-4EFA-B839-BA71297B3985Q49296790-87AB1017-D3BE-47EC-82FB-68E42516848C
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Targetless T cells in cancer immunotherapy.
@en
type
label
Targetless T cells in cancer immunotherapy.
@en
prefLabel
Targetless T cells in cancer immunotherapy.
@en
P2860
P1476
Targetless T cells in cancer immunotherapy.
@en
P2093
Federico Garrido
P2860
P2888
P356
10.1186/S40425-016-0127-Z
P577
2016-04-19T00:00:00Z
P6179
1012879217